Immune thrombocytopenia (ITP) is a rare blood disorder, affecting roughly 3.3 out of every 100,000 adults per year. To put that in perspective, in a city of one million people, only about 33 adults would be newly diagnosed in a given year. At any point in time, about 9.5 per 100,000 adults are living with the condition, making it uncommon enough that many primary care doctors see only a handful of cases in their careers.
How Common Is ITP in Adults vs. Children
ITP occurs at similar rates across age groups, though with some variation. In children, the estimated incidence ranges from 1.9 to 6.4 per 100,000 per year, while adults develop ITP at a rate of about 3.3 per 100,000 per year. The wide range in children reflects differences in how studies define and capture cases, but the overall picture is consistent: ITP is rare at every age.
The disease behaves quite differently depending on when it strikes. About 80% of children with ITP experience spontaneous remission, meaning their platelet counts return to normal without any treatment. In adults, that number drops to roughly 20%. This is one reason adult ITP is more likely to become a long-term condition, while childhood ITP often resolves on its own within weeks or months.
What ITP Actually Does
ITP is an autoimmune condition where your immune system mistakenly targets and destroys your own platelets, the tiny blood cells responsible for clotting. A normal platelet count falls between 150,000 and 400,000 per microliter of blood. ITP is diagnosed when that count drops below 100,000 with no other obvious explanation, such as infection or bone marrow disease.
Many people with ITP have no symptoms at all, especially if their platelet count stays above 50,000 or so. Lower counts can cause easy bruising, tiny red or purple dots on the skin (called petechiae), and prolonged bleeding from minor cuts. The real danger zone begins when platelets fall below 20,000. At that level, the risk of spontaneous bleeding increases significantly. Below 10,000, mucosal bleeding (from the gums, nose, or digestive tract) becomes a serious concern. People taking blood-thinning medications face an even higher risk, with roughly four times the odds of severe bleeding compared to those not on anticoagulants.
Newly Diagnosed, Persistent, and Chronic ITP
Doctors classify ITP based on how long it lasts. A new diagnosis covers the first three months. If low platelet counts persist between 3 and 12 months, it’s called persistent ITP. Beyond 12 months, the condition is classified as chronic. This distinction matters because it shapes treatment decisions and helps set expectations. Someone whose platelets recover within a few weeks has a very different outlook than someone managing the condition years later.
Chronic ITP is more common in adults precisely because spontaneous remission is less likely. Among adults who don’t recover on their own, the condition often requires ongoing management to keep platelet counts in a safe range.
Primary vs. Secondary ITP
Most cases of ITP are considered “primary,” meaning the immune system attacks platelets for no identifiable reason. In some cases, though, ITP develops alongside another condition, such as lupus, hepatitis C, HIV, or certain lymphomas. This is called secondary ITP. The distinction is important because treating the underlying condition can sometimes resolve the low platelet count entirely.
What Treatment Looks Like
Not everyone with ITP needs treatment. If your platelet count stays high enough to prevent bleeding and you have no symptoms, doctors may simply monitor your blood work at regular intervals. Treatment typically becomes necessary when counts drop low enough to pose a bleeding risk or when symptoms like significant bruising or mucosal bleeding develop.
First-line treatment usually involves short courses of steroids to suppress the immune response and allow platelet counts to recover. For people who don’t respond or whose counts drop again after steroids are tapered, second-line options include medications that stimulate the bone marrow to produce more platelets or, less commonly, surgical removal of the spleen (where many platelets are destroyed). The American Society of Hematology published comprehensive treatment guidelines in 2019, and a 2024 review confirmed that those recommendations remain current, with potential updates focused on refining second-line therapy choices.
Living With a Rare Diagnosis
Because ITP is rare, getting a diagnosis can feel isolating. Many people first learn something is wrong through a routine blood test that reveals an unexpectedly low platelet count, not because of dramatic symptoms. The rarity of the condition also means that not every doctor is deeply familiar with it. Hematologists, specialists in blood disorders, are the primary experts who manage ITP long-term.
For most people, ITP is manageable rather than life-threatening. Severe bleeding complications, including intracranial hemorrhage, are uncommon and most often occur in those with extremely low platelet counts below 10,000. The condition does require attention, particularly around situations that increase bleeding risk like surgery, dental work, or starting new medications. But with appropriate monitoring, the majority of people with ITP maintain a normal quality of life despite the diagnosis.